A Validation Study of the NightOwl Home Sleep Apnea Test
Launched by ECTOSENSE NV · Feb 18, 2021
Trial Information
Current as of August 11, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects with an indication for an in-lab polysomnography
- Exclusion Criteria:
- • Intellectually disabled people
About Ectosense Nv
Ectosense NV is a pioneering medical technology company dedicated to advancing sleep health through innovative diagnostic solutions. With a focus on developing non-invasive monitoring devices, Ectosense aims to empower patients and healthcare providers with accurate and actionable insights into sleep disorders, particularly obstructive sleep apnea. By leveraging cutting-edge technology and clinical research, the company strives to enhance patient outcomes and improve the overall management of sleep-related conditions, positioning itself as a leader in the field of sleep medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Miami Lakes, Florida, United States
Coral Springs, Florida, United States
Hollywood, Florida, United States
Pembroke Pines, Florida, United States
Patients applied
Trial Officials
Jagdeep Bijwadia, MD MBA
Principal Investigator
SleepMed RX
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials